Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the Vaccine Efficacy (VE) in the prevention of Herpes Zoster (HZ) over the total duration of the ZOSTER-049 (Z49) study overall as measured by the reduction in HZ risk in subjects ≥50 years of age at the time of first vaccination in the ZOSTER-006/022 (Z6/22) studies.
Critère d'inclusion
- Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination)